4D Pharma PLC ADR (LBPS) Stock
LBPS is no longer traded. 4D Pharma PLC ADR was delisted from the Nasdaq in June 2022.
Prices on this page are historical; the last trade was June 24, 2022 at $1.65.
4D Pharma PLC ADR stock price history
LBPS final trading statistics
- Final close
- $1.65
- Final trading day
- Jun 24, 2022
- Market cap at delisting
- $37.19M
- Shares outstanding
- 22.54M
- Final 52-week range
- $1.50 – $11.09
- Avg. volume (final 3 mo.)
- 45,339
- All-time high (split-adj.)
- $14.55 · Mar 2021
- All-time low (split-adj.)
- $1.56 · Jun 2022
- Return since IPO
- -88.7%
- Beta
- 3.27
- Book value / share
- $1.44
- Price / book
- 1.15
4D Pharma PLC ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $718.0K | -$31.9M | — |
| FY2020 | $534.0K | -$26.0M | -$0.42 |
| FY2019 | $211.0K | -$24.1M | -$0.43 |
| FY2018 | $0.00 | -$23.7M | -$0.48 |
| FY2017 | $0.00 | -$20.4M | -$0.41 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About 4D Pharma PLC ADR
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
4D Pharma PLC ADR stock FAQ
What happened to 4D Pharma PLC ADR stock?
4D Pharma PLC ADR stock was delisted from the Nasdaq. Its final close was $1.65 on June 24, 2022.
Is LBPS stock still trading?
No. LBPS was delisted from the Nasdaq in June 2022 and no longer trades on a U.S. exchange.
What was the last price of LBPS stock?
LBPS closed at $1.65 on its final trading day, June 24, 2022, for a market value of about $37.19M.
What were 4D Pharma PLC ADR's revenue and earnings in its last full fiscal year?
4D Pharma PLC ADR reported revenue of $718.0K and net income of -$31.9M in fiscal 2021, its last full year as a public company.
When did 4D Pharma PLC ADR go public?
4D Pharma PLC ADR stock began trading on March 22, 2021.